Ladder Bio’s Spiroligomer™ platform generates synthetic, DNA‑encoded libraries of rigid fused‑ring molecules that can be computationally designed and screened to produce nanomolar‑affinity protein binders with protease resistance, cell permeability, and low immunogenicity. The company supplies these drug‑like binders and compatible reagents to pharmaceutical, biotech, and diagnostic developers, offering fully synthetic GMP manufacturing that reduces cost and batch variability.
Funding
$5.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current drug discovery and diagnostic pipelines rely heavily on biologics such as antibodies and peptides, which often suffer from limited stability, batch‑to‑batch variability, poor cell permeability, and high manufacturing costs, constraining the development of selective protein‑targeting agents.
Solution
Ladder Bio’s Spiroligomer™ platform delivers a synthetic, modular fused‑ring scaffold that enables precise three‑dimensional shape control and extensive functional‑group diversity. By generating DNA‑encoded libraries containing billions of distinct Spiroligomer molecules, the platform supports high‑throughput computational design and rapid selection of candidates with nanomolar affinity for virtually any protein of interest. The resulting compounds exhibit protease resistance, intrinsic cell permeability, non‑immunogenicity, and potential oral bioavailability, making them suitable for both therapeutic and diagnostic applications. A fully synthetic manufacturing route ensures consistent quality and reduces cost compared with biologic production. Integrated analytics and cloud‑based data pipelines streamline hit validation, lead optimization, and regulatory documentation.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking high‑affinity, drug‑like protein binders, as well as diagnostic developers requiring stable, reproducible synthetic reagents for assay platforms.
Features
- Rigid fused‑ring scaffold offering sub‑angstrom control of molecular geometry for high‑precision protein interface design.
- DNA‑encoded library (DEL) of >4 billion unique Spiroligomer candidates, enabling ultra‑large‑scale screening.
- Computational design workflow that couples structure‑based modeling with machine‑learning scoring to prioritize binders.
- Intrinsic physicochemical properties: protease resistance, high thermal stability, cell permeability, and low immunogenic risk.
- Scalable, fully synthetic GMP manufacturing process that eliminates batch variability and lowers COGS.
- Antibody‑like binding affinity with customizable functional groups for enzyme inhibition, receptor modulation, or assay capture.
- Compatibility with standard diagnostic formats (ELISA, lateral flow, biosensor) through facile conjugation chemistries.